| abstract |
The present invention relates to new phenanthridine derivatives of the formula (I) wherein R is a hydrogen atom or a C-C1-6 alkyl group; R is selected from (1) a hydrogen atom with the condition that R and R cannot simultaneously be a hydrogen atom; (2) - (CH) -NRR, (3) - (CH) -CO-NRR, (4) - (CH) -XQ, (5) - (CHR-NRR; or R and R together with the nitrogen atom to which they are attached to form a 4-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from O, S and N; wherein said ring is optionally substituted with —CO — NRR, C — C1-6 alkyl, 4- (4,5-dihydro- 1H-imidazol-2-yl) benzyl or 4- (1,4,5,6-tetrahydropyrimidin-2-yl) benzyl; R, R, R, R and R are independently from each other a hydrogen atom, a halogen atom, trifluoromethyl, C -Salkyl, C-Salkoxy- or acetyl group; n is an integer from 1 to 4; R and R are a hydrogen atom, not necessarily substituted by a C-C1-6 alkyl group, or R, R, and the nitrogen atom to which they are attached together form a saturated, partially unsaturated or aromatic 4-7 membered ring comprising 1-3 heteroatoms selected from O, S and N; where said ring optionally substituted with a 1-piperidinyl, 2-piperidinyl, 4-piperidinyl, 2-pyridyl or 4-pyridyl group; R is a methyl, hydroxymethyl, benzyl or phenyl group; m is an integer from 0 to 6; X is a single bond, O or S; Q is a phenyl group optionally substituted with [1,4 '] - bipiperidinyl-1'-yl, 4,5-dihydro-1H-imidazol-2-yl, - (CH) -NH- (C = NH) -NH or - (CH) - (C = NH) -NH group; or a 4-piperidinyl group optionally substituted with a 4-piperidinyl group; or a C-Cycloalkyl group optionally substituted with - (CH) -NRR group, and their optical antipodes, or racemates, and / or salts, and / or hydrates, and / or solvates; to the processes of their production, to pharmacological compositions including them, and to their use in the treatment |